Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058422 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT00058422: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00058422 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00058422, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan in treating older patients who have B-cell lymphoma that has not been previously treated.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL rituximab
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- BIOLOGICAL darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2003-02-10 |
| Est. Completion | 2019-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058422
The ClinicalTrials.gov registry entry for NCT00058422 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00058422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058422 about?
NCT00058422 is a clinical study titled "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma". RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividin...
What is the current status of trial NCT00058422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2003-02-10. Estimated completion is 2019-11-14.
What interventions are being tested in trial NCT00058422?
The interventions under investigation include: cyclophosphamide (DRUG), rituximab (BIOLOGICAL), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), darbepoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00058422?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.